In episode 561, Mike and James invite Adrienne Lindblad and Mike Kolber to discuss our recently revised 2023 simplified lipid guidelines. We talk about the guideline process, the best available eviden

In episode 560, Mike and James finish their discussion around the use of hallucinogens/psychedelics by going over the psilocybin evidence. As with ketamine we cover the many limitations of the evidenc

In episode 559, Mike and James continue to discuss the best available evidence around ketamine and severe depression. We go over the many limitations of the evidence and at the end we wrap it all up b

In episode 558, Mike and James decide to start to tackle the ketamine for depression story. Mike talks about what the media says about ketamine and then he delves into what the guidelines say. Then as

Episode 557: Fancy Creams for Scaly Skin: Topical calcineurin inhibitors for atopic dermatitis In episode 557, Mike and James invite Emelie Braschi back to the podcast to talk about how effective topi

In episode 556, Mike and James have Betsy Thomas back to podcast to talk about how effective are artificial tears for people with dry eyes. Both of us cry halfway through the podcast because of the cr

In episode 555, James and Mike invite Jamie Falk back to the podcast to talk about the best available evidence for acetylsalicylic acid and its potential impact on reducing the risk of complications i

In episode 554, James and Mike go over a topic we have never covered in 553 previous podcasts. We invited Samantha Moe back to the podcast to talk about how effective are pelvic floor exercises or pes

In episode 553, James and Mike get Jen Potter back to talk about the last option we have for heavy menstrual bleeding tranexamic acid. We talk about how it compares to placebo, NSAIDs, progestins an

In episode 552, James and Mike go over a couple of new trials. We talk about a blood pressure trial that examined taking the pills in the morning vs the evening and a heart failure trial that looked a